Apex Medical Corp.
TWSE:4106.TW
22.05 (TWD) • At close August 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,386.654 | 2,647.122 | 2,663.723 | 2,374.055 | 2,004.025 | 2,036.232 | 2,105.748 | 2,089.277 | 1,990.275 | 2,015.894 | 2,263.357 | 2,016.971 | 1,845.771 | 1,748.518 | 1,661.216 | 1,577.269 |
| Cost of Revenue
| 1,311.804 | 1,508.805 | 1,596.935 | 1,387.103 | 1,156.394 | 1,182.415 | 1,228.877 | 1,182.754 | 1,112.094 | 1,114.729 | 1,216.822 | 1,165.974 | 1,104.251 | 1,114.883 | 1,025.534 | 979.348 |
| Gross Profit
| 1,074.85 | 1,138.317 | 1,066.788 | 986.952 | 847.631 | 853.817 | 876.871 | 906.523 | 878.181 | 901.165 | 1,046.535 | 850.997 | 741.52 | 633.635 | 635.682 | 597.921 |
| Gross Profit Ratio
| 0.45 | 0.43 | 0.4 | 0.416 | 0.423 | 0.419 | 0.416 | 0.434 | 0.441 | 0.447 | 0.462 | 0.422 | 0.402 | 0.362 | 0.383 | 0.379 |
| Reseach & Development Expenses
| 163.526 | 165.762 | 154.283 | 150.746 | 167.827 | 138.194 | 132.163 | 138.934 | 102.931 | 94.504 | 88.557 | 79.883 | 83.888 | 82.506 | 77.233 | 69.965 |
| General & Administrative Expenses
| 375.072 | 399.368 | 346.897 | 362.973 | 307.525 | 307.265 | 317.452 | 331.286 | 355.998 | 350.047 | 474.486 | 284.152 | 158.785 | 124.507 | 103.035 | 108.097 |
| Selling & Marketing Expenses
| 389.805 | 379.127 | 379.485 | 369.226 | 275.461 | 273.896 | 290.413 | 284.726 | 259.953 | 246.861 | 258.697 | 304.597 | 259.468 | 211.174 | 230.866 | 178.159 |
| SG&A
| 764.877 | 778.495 | 726.382 | 732.199 | 582.986 | 581.161 | 607.865 | 616.012 | 615.951 | 596.908 | 733.183 | 588.749 | 418.253 | 335.681 | 333.901 | 286.256 |
| Other Expenses
| 14.738 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 943.141 | 944.098 | 880.665 | 882.945 | 750.813 | 719.355 | 740.028 | 754.946 | 718.882 | 691.412 | 821.74 | 668.632 | 502.141 | 418.187 | 411.134 | 356.221 |
| Operating Income
| 131.709 | 194.219 | 211.903 | 145.435 | 132.006 | 152.121 | 136.843 | 151.577 | 159.299 | 209.753 | 224.795 | 182.365 | 239.379 | 215.448 | 224.548 | 241.7 |
| Operating Income Ratio
| 0.055 | 0.073 | 0.08 | 0.061 | 0.066 | 0.075 | 0.065 | 0.073 | 0.08 | 0.104 | 0.099 | 0.09 | 0.13 | 0.123 | 0.135 | 0.153 |
| Total Other Income Expenses Net
| 16.135 | 15.634 | 15.597 | 33.758 | 12.581 | -6.036 | 13.428 | 0.189 | 2.831 | 14.879 | 27.178 | 21.192 | 25.083 | 25.357 | -2.629 | 2.019 |
| Income Before Tax
| 147.844 | 209.853 | 200.537 | 138.081 | 124.844 | 128.426 | 150.271 | 151.766 | 162.13 | 224.632 | 251.973 | 203.557 | 264.462 | 269.546 | 221.919 | 257.772 |
| Income Before Tax Ratio
| 0.062 | 0.079 | 0.075 | 0.058 | 0.062 | 0.063 | 0.071 | 0.073 | 0.081 | 0.111 | 0.111 | 0.101 | 0.143 | 0.154 | 0.134 | 0.163 |
| Income Tax Expense
| 32.193 | 56.841 | 38.423 | 34.57 | 19.467 | 39.622 | 40.954 | 34.083 | 39.443 | 50.699 | 53.867 | 57.328 | 59.356 | 35.648 | 42.478 | 48.689 |
| Net Income
| 115.239 | 152.172 | 161.404 | 102.247 | 104.588 | 87.921 | 108.413 | 118.263 | 122.504 | 168.745 | 178.414 | 133.466 | 196.22 | 232.561 | 180.681 | 212.185 |
| Net Income Ratio
| 0.048 | 0.057 | 0.061 | 0.043 | 0.052 | 0.043 | 0.051 | 0.057 | 0.062 | 0.084 | 0.079 | 0.066 | 0.106 | 0.133 | 0.109 | 0.135 |
| EPS
| 1.14 | 1.51 | 1.6 | 1.01 | 1.04 | 0.87 | 1.17 | 1.42 | 1.47 | 2.02 | 2.14 | 1.6 | 2.25 | 2.79 | 2.17 | 2.55 |
| EPS Diluted
| 1.14 | 1.5 | 1.59 | 1.01 | 1.03 | 0.87 | 1.13 | 1.34 | 1.45 | 2.01 | 2.13 | 1.59 | 2.23 | 2.77 | 2.16 | 2.54 |
| EBITDA
| 256.026 | 318.123 | 305.214 | 238.981 | 211.28 | 232.966 | 226.138 | 250.943 | 272.539 | 330.651 | 364.403 | 311.451 | 319.746 | 285.843 | 240.846 | 309.266 |
| EBITDA Ratio
| 0.107 | 0.12 | 0.115 | 0.101 | 0.105 | 0.114 | 0.107 | 0.12 | 0.137 | 0.164 | 0.161 | 0.154 | 0.173 | 0.163 | 0.145 | 0.196 |